Intelligent Bio Solutions expects to achieve 32.6% Gross Profit Expansion and Increased Profitability on Higher-Margin Sales

Gross profit expected to surge by 32.6% Unaudited revenue of $0.61 million for fiscal Q2 and$1.48 million for the six months ended December 31, 2024 Higher-margin cartridge sales driving profitability and long-term growth Expanding U.S. and international market presence with FDA submission and strategic partnerships NEW YORK, Feb. 06, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive tes ...